26 December 2017 - Australia relies on managed entry agreements for many medicines added to the national Pharmaceutical Benefits Scheme. 

Previous studies of Australian managed entry agreements (MEAs) examined public domain documents and were not able to provide a comprehensive assessment of the types and operation of MEAs. This study used government documents approved for release to examine the implementation and administration of MEAs implemented January 2012 to May 2016.

Of all medication indication pairs (MIPs) recommended for listing, one-third had MEAs implemented. Our study of eighty-seven MIPs had 170 MEAs in place.

Read International Journal of Technology Assessment in Health Care article